Ariana Pelosci

Patients who developed brain metastases from renal cell carcinoma experienced promising intracranial activity after being treated with cabozantinib.

Patients with melanoma, head and neck squamous cell carcinoma, and cervical cancer who had not previously received immunotherapy and were treated with lifileucel plus pembrolizumab experienced promising overall response rates compared favorably with historical data on pembrolizumab monotherapy.

Patients with relapsed/refractory adult B-cell acute lymphoblastic leukemia who were treated with AUTO1 experienced durable responses.

Patients with hormone receptor–positive breast cancer in 3 separate subgroups showed an overall survival benefit when treated with eftilagimod alpha plus paclitaxel compared with the placebo.

Cell therapy omidubicel, designed for patients with hematologic malignancies who are undergoing allogeneic stem cell transplant, will be submitted to the FDA for approval in 2022.

Patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer treated with first-line nivolumab plus low-dose ipilimumab experienced a durable clinical benefit.

Patients who are White British and have been diagnosed with a malignant primary brain tumor were found to have a shorter survival compared with patients of other ethnicities.

The single-cell functional precision medicine treatment, an artificial intelligence strategy helps to create therapies for patients with hematologic cancers.

Germline testing for BRCA1/2 mutations in tumor tissue for treatment selection of PARP inhibition in HER2-negative metastatic breast cancer did not show large differences in outcomes compared with blood testing, inferring feasibility of tumor testing.

The utilization of 68Ga-PSMA-11 PET allowed for positive sensitivity and specificity scores for patients with intermediate to high-risk prostate cancer following radical prostatectomy and lymph node dissection.

Patients with mutant-IDH2 acute myeloid leukemia experienced a better overall response rate when treated with enasidenib plus azacitidine compared with azacitidine alone.

A comparative study indicated that patients with advanced ovarian cancer who received high and low doses of neoadjuvant chemotherapy experienced similar improvements in overall survival.

Findings from a study indicated that non-Hispanic American Indian and Alaskan Native patients with breast cancer were more likely to undergo a mastectomy compared with non-Hispanic White patients.

As lenvatinib plus pembrolizumab combination therapy results in a wide range of adverse effects, some which even led to discontinuation of the treatment, investigators suggest a proactive strategy for patients with advanced renal cell carcinoma.

Patients with cancer who have underwent radiotherapy within 6 months did not experience any notable safety concerns after receiving the Moderna mRNA-1273 vaccine.

Camrelizumab plus apatinib demonstrated efficacious anti-tumor activity and could be a worthwhile salvage therapy in high-risk chemorefractory or relapsed gestational trophoblastic neoplasia.

Patients who had a poor pathological response to preoperative chemoradiation for advanced rectal cancer and waited 8 weeks or longer for surgery were likely to experience poor overall disease-free survival after completing neoadjuvant chemoradiotherapy.

Patients with invasive HE2-positive breast cancer who were treated with pegylated liposomal doxorubicin plus docetaxel and trastuzumab experienced an increase in a pathological complete response.

Lifileucel, a tumor infiltrating therapy, could be the best treatment for heavily pretreated patients with advanced melanoma, with investigators at Atlantic Health System examining this treatment modality in clinical trials.

UV1 has received fast track designation from the FDA for the use in unresectable or metastatic melanoma.

Patients with hormone receptor–positive, ERBB2-negative advanced breast cancer experienced significant anti-tumor activity when treated with fulvestrant and palbociclib but did not see an improvement in progression-free survival compared with letrozole and palbociclib .

The FDA granted priority review to a new drug application for parsaclisib in patients with mantle cell lymphoma and other non-Hodgkin lymphomas.

For Pancreatic Cancer Awareness Month, CancerNetwork® spoke with Allyson Ocean, MD, about how family members of patients with pancreatic cancer should seek genetic testing to determine if they are predisposed to pancreatic cancer.

On or after week 5 of treatment with chemotherapy, trilaciclib reduced the need for supportive care therapies in patients with extensive-stage small-cell lung cancer.

Patients treated with eryaspase for second line advanced pancreatic cancer did not meet the primary end point of overall survival in the TRYbeCA-1 trial.

The AVENIO Tumor Tissue Comprehensive Genomic Profiling Kit could allow for more accessible genetic testing and result in more personalized treatments.

Although canakinumab, an investigational interleukin-1β inhibitor, plus pembrolizumab did not meet the primary end points for locally advanced metastatic non–small cell lung cancer in the CANOPY-1 trial, it could have potential in certain patient subgroups.

Patients receiving trastuzumab for HER2-positive breast cancer on the phase 3 HERA trial did not have an increased risk of cardiotoxicity from radiation therapy.

Stereotactic body radiotherapy added to standard of care treatment resulted in better progression-free survival for those with oligoprogressive non–small cell lung cancer.

The interim results of a phase 1b/2 trial showed that patients with soft tissue sarcoma and lung metastases who were treated with annamycin experienced positive clinical activity.